Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
LLY Stock Chart & Stats
$1054.29
$17.01(2.20%)
At close: 4:00 PM EST
$1054.29
$17.01(2.20%)
Day’s Range― - ―
52-Week Range$623.78 - $1,111.99
Previous CloseN/A
Volume1.27M
Average Volume (3M)3.96M
Market Cap
$996.71B
Enterprise Value$718.43B
Total Cash (Recent Filing)$9.91B
Total Debt (Recent Filing)$42.51B
Price to Earnings (P/E)52.1
Beta0.65
Next Earnings
Feb 11, 2026EPS Estimate
7.16Next Dividend Ex-DateN/A
Dividend Yield0.61%
Share Statistics
EPS (TTM)7.02
Shares Outstanding945,383,700
10 Day Avg. Volume3,414,913
30 Day Avg. Volume3,962,909
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)48.99
Price to Sales (P/S)15.44
P/FCF Ratio1.68K
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue12.09
Enterprise Value/Gross Profit14.56
Enterprise Value/Ebitda28.40
Forecast
1Y Price Target
$1,135.32Price Target Upside7.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)23.82
Revenue Forecast (FY)$63.75B
Bulls Say, Bears Say
Bulls Say
Government DealThe recent US government deal is expected to mitigate risks related to GLP1 pricing and obesity competition, along with Lilly’s broad obesity pipeline.
Obesity Drug LaunchesLilly shares can continue to appreciate as LLY executes key obesity launches and de-risks new therapies in nearly every conceivable market segment.
Retatrutide EfficacyRetatrutide showed weight loss up to 28.7% in patients with obesity and osteoarthritis of the knee, which is an encouraging early efficacy look.
Bears Say
Adverse EventsAdverse events with retatrutide were consistent with other obesity medications but overall slightly higher, particularly dysesthesia occurring in 8.8%/20.9% of patients at the 9mg/12mg doses.
Pricing ConcernsDespite reduced prices for cash pay Zepbound, the product is still priced at a premium compared to Novo's cash pay Wegovy.
Safety ProfileA negative scenario with less than 20% weight loss or a concerning safety profile could raise questions about Retatrutide's benefit-risk profile.
Eli Lilly & Co News
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $623.78 and its highest was $1111.99 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Eli Lilly & Co’s market cap is $996.71B.
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Feb 11, 2026 which is in 55 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Oct 30, 2025. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $5.692 by $1.328.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.5 which represents an annual dividend yield of 0.61%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is 7.16.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 945,383,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $7.02 in its last earnings report, beating expectations of $5.692. Following the earnings report the stock price went up 3.806%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Currently, no hedge funds are holding shares in LLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,135.32 (7.69% Upside)
$1,135.32 (7.69% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 90%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $79.0B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.34%
12-Months-Change
Fundamentals
Return on Equity
96.82%
Trailing 12-Months
Asset Growth
52.02%
Trailing 12-Months
Company Description
Eli Lilly & Co
Eli Lilly & Co (LLY) is a global pharmaceutical company headquartered in Indianapolis, Indiana, specializing in the development, manufacturing, and marketing of innovative medicines. The company operates primarily in the biopharmaceutical sector and focuses on several therapeutic areas, including diabetes, oncology, immunology, neuroscience, and men's and women's health. Eli Lilly is known for its portfolio of leading medications, such as insulin products, cancer therapies, and treatments for mental health disorders, aimed at improving patient outcomes and enhancing the quality of life for individuals worldwide.
LLY Company Deck
LLY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong quarter with significant revenue growth, increased market share, and notable FDA and EU approvals. However, the company faced challenges with price declines in the U.S. and increased expenses. Despite these challenges, the overall sentiment is positive due to the strong financial performance and strategic advancements.View all LLY earnings summariesLLY Revenue Breakdown
90.47% Net product revenue
9.53% Collaboration and other revenue
LLY Stock 12 Month Forecast
Average Price Target
$1,135.32
▲(7.69% Upside)
Technical Analysis
Ownership Overview
9.90% Insiders
22.66% Mutual Funds
27.48% Other Institutional Investors
21.89% Public Companies and Individual Investors